Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To demonstrate superiority of 500 mg and 250 mg Aspirin® i.v. (BAY 81-8781) treatment over oral treatment with 300 mg Aspirin® N tablets to inhibit thromboxane A2-release (measured as stable metabolite thromboxane B2 in serum, TXB2) at 5 minutes after single dose of study drug administration. Thromboxane release is a surrogate parameter for the inhibition of platelet aggregation and thrombus formation in vivo
Inclusion criteria
- Acute coronary syndrome (ACS)